Trichloroacetic acid
PreclinicalSmall molecule
Trichloroacetic acid is one of 40 small molecule programs targeting Epistaxis. It is currently in Preclinical.
2
Indications
8
Total Trials
0
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
35 competitors in Alopecia Areata
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsApproved
Otezla
AmgenApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Zolymbus
AbbVieApproved
Daliresp
AstraZenecaApproved
Xeljanz
PPrism Pharmaceuticals
Approved
Anzupgo
Jazz PharmaceuticalsApproved
Zocor
OOrganon and Co
Approved
Xalatan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metformin1 trial
USE THE SYSTEMIC METFORMIN IN MELASMA
Unknown status·—·Phase 4·NCT03475524·60 enrolled
Adjuvant Therapy1 trial
Trichloroacetic Acid1 trial
Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic Acid
Unknown status·—·Phase 4·NCT03153852·30 enrolled
Alopecia Areata1 trial
New Treatment of Alopecia Areata
Completed·—·N/A·NCT05594316·40 enrolled
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trichloroacetic acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIndonesia University